Register entry
- Registered sites
- 0
- Active NDC listings
- 4
- Live patents
- 0
- Countries
- 0
Catalogue
Drug listings by form and route
44 active NDC listings: 4 drug for further processing. By marketing category: DRUG FOR FURTHER PROCESSING 4.
| Dosage form | NDCs |
|---|---|
| injection, solution | 3 |
| injection, solution, concentrate | 1 |
| Route | NDCs |
|---|
| Labeller name on the listing | NDCs |
|---|---|
| sanofi-aventis deutschland gmbh | 4 |
Catalogue
Marketed products
4| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| - | fitusiran | injection, solution | 12854-310DRUG FOR FURTHER PROCESSING |
| - | insulin aspart-szjj | injection, solution | 12854-050DRUG FOR FURTHER PROCESSING |
| - | insulin aspart-szjj | injection, solution | 12854-060DRUG FOR FURTHER PROCESSING |
| - | isatuximab | injection, solution, concentrate | 12854-659DRUG FOR FURTHER PROCESSING |
Compare
Other companies listing insulin aspart-szjj
- sanofi-aventis U.S. LLC0 sites · 83 NDC
Enquiry
Common questions
- Is Sanofi-Aventis Deutschland GmbH FDA approved?
- Sanofi-Aventis Deutschland GmbH holds no registered establishment of its own; 4 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Sanofi-Aventis Deutschland GmbH make?
- 4 products are listed under Sanofi-Aventis Deutschland GmbH in the openFDA NDC Directory, most often as injection, solution; injection, solution, concentrate. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.